Delivery Order SPE2DB24D3013-SPE2DB26FFFWV
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 8, 2025, for the supply of Rexulti 0.5 mg tablets (30-count) with a ceiling value of $1,952.46. This is a firm fixed price delivery order with no set-aside designation, issued under a competitive process. The contract is due for completion by August 11, 2025, and will be performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania. This award represents a child order under the company's...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 9, 2025, for the supply of Rexulti 0.5 mg tablets in a 30-count package. This firm fixed-price delivery order, valued at $3,904.92, is scheduled for completion by September 10, 2025, with performance at the contractor's facility in Conshohocken, Pennsylvania. The award was competitively procured with no set-aside designation, reflecting AmerisourceBergen's capability to meet federal pharmaceutical...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 5, 2025, for the supply of Rexulti 2 mg tablets (30-count packages) with a ceiling value of $9,967.07. This competitively awarded, firm fixed-price delivery order is scheduled for completion by September 8, 2025, and will be fulfilled from AmerisourceBergen's operations in Conshohocken, Pennsylvania. The contract carries no set-aside designation, indicating open competition among qualified...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on October 24, 2025, for the supply of Rexulti 2 mg tablets (30-count packages) valued at $4,531.84. This is a firm fixed-price delivery order with no set-aside designation, indicating the award was made through open competition. The order is scheduled for ultimate completion by October 27, 2025, with performance taking place at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This...
- The Defense Logistics Agency awarded a delivery order valued at $1,278.42 to AmerisourceBergen Drug Corp for the supply of Rexulti 2 mg tablets (30-count) on August 21, 2025, with completion scheduled for August 22, 2025. This is a firm fixed-price delivery order with no set-aside designation, competitively awarded through open competition. The pharmaceutical product will be delivered to the vendor's location in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 14, 2025, for the supply of Rexulti 1 mg tablets in a 30-count package, with a contract ceiling value of $4,260.21. This non-set-aside, competitively awarded delivery order represents a firm fixed price transaction and is scheduled for completion by August 15, 2025. The work will be performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania. This delivery order is issued under...
- The Defense Logistics Agency awarded a $41,480.93 delivery order to AmerisourceBergen Drug Corp on July 28, 2025, for the supply of Rexulti 1 mg tablets (30-count units). This firm fixed-price, competitively awarded contract with an ultimate completion date of July 29, 2025, represents a child order under AmerisourceBergen's larger pharmaceutical supply vehicle with the DLA. The product will be delivered to the company's corporate office location in Conshohocken, Pennsylvania, where...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 22, 2025, for the supply of Rexulti 1 mg tablets (30-count units) with a ceiling value of $6,446.12. This firm fixed-price delivery order is part of AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, valued at $999,999,999.00 and extending through December 2026. The contract is non-set-aside and was competitively awarded....
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 8, 2025, for the supply of Rexulti 2 mg tablets in a quantity of 30 units, with a ceiling value of $2,927.61. This is a firm fixed price delivery order with an ultimate completion date of August 11, 2025, and represents a non-competitive set-aside award. The order will be performed at the contractor's location in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate office. This...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 29, 2025, for the supply of Rexulti 1 mg tablets in a 30-count package, with a contract ceiling value of $27,653.67. This is a firm fixed-price delivery order with no set-aside designation, indicating the award resulted from open competitive procurement. The ultimate completion date is set for September 30, 2025, and the place of performance is AmerisourceBergen's corporate office in Conshohocken,...
- SPE2DB24D3013Indefinite Delivery Contract
- SPE2DB24D3013-SPE2DB26FFFWVDelivery Order
The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on October 27, 2025, for the supply of Rexulti 0.5 mg tablets in a quantity of 30 units, with a ceiling value of $1,597.63. This firm fixed-price delivery order is set to be completed by October 28, 2025, and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. The award was made through open competition without any set-aside designation, reflecting AmerisourceBergen's demonstrated capability to meet federal pharmaceutical procurement requirements. This delivery order is a child contract issued under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. This prime contract vehicle enables the company to supply a comprehensive range of pharmaceutical products and medical supplies to support military healthcare systems globally. Rexulti, an atypical antipsychotic medication used in treating major depressive disorder and schizophrenia, represents one of the specialized pharmaceutical products AmerisourceBergen delivers through its extensive federal medical supply contracts that serve the Defense Health Agency, U.S. Coast Guard, and other government healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.6k | 10/27/25 |